Gilead Sciences has the data it’ll need to start transitioning patients taking Truvada for PrEP over to Descovy, a drug with a longer patient life. But once Truvada generics hit, it might be a ...
One big task for Gilead Sciences’ HIV franchise in the coming year is to save some $2.5 billion in annual sales by switching as many PrEP patients as possible from Truvada to newly approved Descovy ...
Add Yahoo as a preferred source to see more of our stories on Google. A major health insurer has notified policy holders that it will no longer cover Gilead Sciences’ drug Descovy for pre-exposure ...
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ: GILD) today presented additional results from the DISCOVER trial evaluating an investigational use of Descovy (emtricitabine 200 ...
Descovy demonstrated continued noninferiority to Truvada for HIV pre-exposure prophylaxis and statistically significant differences over Truvada for pre-specified secondary end points. In the phase 3, ...
Add Yahoo as a preferred source to see more of our stories on Google. Today, the U.S. Food and Drug Administration approved Gilead’s drug Descovy to be used as PrEP, an HIV prevention strategy that ...
The FDA has approved Descovy for HIV-1 pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents (≥35kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results